课题基金 / 基金详情

PA-20-070: Partnership for Medication Safety in Primary Care and Telehealth during COVID-19 Public Health Crisis

PA-20-070: Partnership for Medication Safety in Primary Care and Telehealth during COVID-19 Public Health Crisis
PA-20-070:COVID-19 公共卫生危机期间初级保健和远程医疗中的药物安全合作伙伴关系
批准号:
10175928
负责人:
Yan Xiao
金额:
$37.6万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-30 至 2023-09-29

项目摘要

项目成果

Yan Xiao的其他基金

相似基金

相关文献

中文摘要
翻译
这一为期一年的修订补充母项目("PROMIS实验室:伙伴关系的恢复, 药物安全"或" PROMIS实验室")是为了满足迫切需要,以帮助解决及时的卫生系统和 医疗保健专业人员应对COVID-19公共卫生危机。我们的研究是评估 在应对COVID-19公共卫生危机时,初级保健服务受到两次广泛干扰。一 没有能力或不愿意去初级诊所,导致延误或错过护理。另一个是使用 远程保健模式,以减少对病原体的接触。然而,某些访问(例如,验血(必须 在平衡患者需求和COVID-19相关社交距离规则的同时,我们指 将不同类型的访问作为多种参与模式。这两种类型的中断都有直接影响 对病人安全的影响可能是负面的修订补充文件中的拟议研究迫切需要 needed. 2019冠状病毒病公共卫生危机给基层医疗诊所带来前所未有的混乱。 了解危机对患者安全的影响,为差距和最佳实践提供证据, 确保患者安全。我们将针对健康差距大、得不到充分服务的人群, 经历了COVID-19带来的更高死亡率, 与物流相关的障碍因健康的社会决定因素而加剧。修订的具体目标 补充是为了评估参与模式的影响,如远程保健,对医疗服务的获得和 在COVID-19大流行期间的安全。在评估的基础上,我们将把调查结果综合应用于实践 指导方针,以支持初级保健诊所和组织,以应对 流行病我们将通过四个子目标实现这一目标:(a)描述由于 通过审查行政和临床数据,评估初级保健服务中的COVID-19,(B)。 通过与一线人员进行定性访谈研究, 临床医生和管理人员,(c).使用远程医疗访问模式评估患者参与度, 通过针对具有药物安全问题已知风险因素的患者进行调查,以及(d).制定指南 向初级保健诊所提供改善安全的方法,以减轻COVID-19大流行的影响, 专家小组和模拟建模的不同调度实践的各种形式的病人访问。 拟议的补编研究活动的设计是高度可行的, 时间轴,与母项目同时完成。拟议活动 利用母项目PROMIS实验室的临床合作伙伴和研究专业知识,并将使用 类似的方法,以评估不同类型诊所和患者人群的患者安全性, 部分原因是采用和使用不同的患者参与模式。
英文摘要
This one-year Revision Supplement to the parent project (“PROMIS Lab: Partnership in Resilience for Medication Safety” or “PROMIS Lab”) is to meet immediate needs to help address timely health system and healthcare professional response to the COVID-19 public health crisis. Our research is to evaluate the impact from two broad disruptions to primary care delivery in the response to the COVID-19 public health crisis. One is the inabilities or reluctance to visit primary clinics, resulting in delayed or missed care. Another is the use of telehealth modalities, to reduce exposure to pathogens. However, certain visits (e.g., blood test) must be performed in person, while balancing patient needs and COVID-19 associated social distancing rules. We refer to the different types of visits as multiple engagement modalities. Both types of disruptions have direct impact on patient safety, presumably negatively. The proposed research in the Revision Supplement is urgently needed. Primary care clinics face unprecedented disruption brought by the COVID-19 public health crisis. Understanding the impact of the crisis on patient safety provide evidence to gaps and to best practices to ensure patient safety. We will target underserved populations with health disparity, as such populations have experienced disproportionally higher mortalities from COVID-19 while they are subjected to technology and logistics associated barriers exacerbated by social determinants of health. The specific aim of the Revision Supplement is to evaluate the impact of engagement modalities, such as telehealth, on healthcare access and safety during COVID-19 Pandemic. Based on the evaluation, we will synthesize findings into practice guidelines to support primary care clinics and organizations in responding to unique challenges posed by the pandemic. We will achieve the aim with four subaims: (a).Characterize disruptions and adaptation due to COVID-19 in primary care delivery by reviewing administrative and clinical data, (b).Assess barriers and facilitators in primary care delivery due to COVID-19 by conducting qualitative interview studies with frontline clinicians and administrators, (c).Evaluate patient engagement using telehealth visit modalities using post-visit surveys by targeting patients with known risk factors for medication safety concerns, and (d).Develop guidance to primary care clinics on ways to improve safety to mitigate the impact of the COVID-19pandemic, through expert panels and simulation modeling of different scheduling practices for various modalities of patient visits. The proposed Supplement research activities are designed to be highly feasible with the short, one-year timeline, to be accomplished in parallel and in conjunction of the parent project. The proposed activities capitalize on the clinical partners and research expertise in the parent project PROMIS Lab, and will use similar methodologies, to evaluate patient safety across different types of clinics and patient populations, in part due to the adoption and usage of different patient engagement modalities.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PROMIS Learning Lab: Partnership in Resilience for Medication Safety
  • 批准号:
    10488623
  • 项目类别:
  • 资助金额:
    $62.5万
  • 财政年份:
    2019
  • 负责人:
    Yan Xiao
  • 依托单位:
PROMIS Learning Lab: Partnership in Resilience for Medication Safety
  • 批准号:
    9903883
  • 项目类别:
  • 资助金额:
    $62.5万
  • 财政年份:
    2019
  • 负责人:
    Yan Xiao
  • 依托单位:
PROMIS Learning Lab: Partnership in Resilience for Medication Safety
  • 批准号:
    10016289
  • 项目类别:
  • 资助金额:
    $62.5万
  • 财政年份:
    2019
  • 负责人:
    Yan Xiao
  • 依托单位:
PROMIS Learning Lab: Partnership in Resilience for Medication Safety
  • 批准号:
    10251914
  • 项目类别:
  • 资助金额:
    $62.5万
  • 财政年份:
    2019
  • 负责人:
    Yan Xiao
  • 依托单位:
国内基金
海外基金
CCL20/CCR6/SEMA3C信号轴通过EMT及肿瘤干细胞互作调控阴茎癌转移的分子机制研究
  • 批准号:
    2026JJ50313
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    胡希恒
  • 依托单位:
CDC20-HDAC6-POLD1轴调控肺腺癌免疫微环境的机制研究
  • 批准号:
    2026JJ80369
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    胡智
  • 依托单位:
USP20调控泛素化修饰介导微卫星稳定型结直肠癌免疫逃逸的机制研究
巴多昔芬通过重编程肿瘤相关巨噬细胞抑制CCL20介导的Treg募集并增敏乳腺癌免疫治疗的机制研究
  • 批准号:
    JCZRQNB202600315
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位: